Literature DB >> 27658726

Neuroendocrinology: New hormone treatment for obesity caused by POMC-deficiency.

Malcolm J Low1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27658726     DOI： 10.1038/nrendo.2016.156

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

Review 1.  Melanocortin-4 receptor modulators for the treatment of obesity: a patent analysis (2008-2014).

Authors:  Esther C Y Lee; Philip A Carpino
Journal:  Pharm Pat Anal       Date:  2015

2.  Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass.

Authors:  A S Chen; D J Marsh; M E Trumbauer; E G Frazier; X M Guan; H Yu; C I Rosenblum; A Vongs; Y Feng; L Cao; J M Metzger; A M Strack; R E Camacho; T N Mellin; C N Nunes; W Min; J Fisher; S Gopal-Truter; D E MacIntyre; H Y Chen; L H Van der Ploeg
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

3.  Unexpected clinical features in a female patient with proopiomelanocortin (POMC) deficiency.

Authors:  Samim Özen; Nurhan Özcan; Sema Kalkan Uçar; Damla Gökşen; Şükran Darcan
Journal:  J Pediatr Endocrinol Metab       Date:  2015-05       Impact factor: 1.634

4.  RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals.

Authors:  Kong Y Chen; Ranganath Muniyappa; Brent S Abel; Katherine P Mullins; Pamela Staker; Robert J Brychta; Xiongce Zhao; Michael Ring; Tricia L Psota; Roger D Cone; Brandon L Panaro; Keith M Gottesdiener; Lex H T Van der Ploeg; Marc L Reitman; Monica C Skarulis
Journal:  J Clin Endocrinol Metab       Date:  2015-02-12       Impact factor: 5.958

5.  Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

Authors:  Peter Kühnen; Karine Clément; Susanna Wiegand; Oliver Blankenstein; Keith Gottesdiener; Lea L Martini; Knut Mai; Ulrike Blume-Peytavi; Annette Grüters; Heiko Krude
Journal:  N Engl J Med       Date:  2016-07-21       Impact factor: 91.245

6.  Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice.

Authors:  K Ganesh Kumar; Gregory M Sutton; Jesse Z Dong; Pierre Roubert; Pascale Plas; Heather A Halem; Michael D Culler; Hyunwon Yang; Vishwa D Dixit; Andrew A Butler
Journal:  Peptides       Date:  2009-07-29       Impact factor: 3.750

7.  Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist.

Authors:  Jocelyn M Bischof; Lex H T Van Der Ploeg; William F Colmers; Rachel Wevrick
Journal:  Br J Pharmacol       Date:  2016-07-27       Impact factor: 8.739

8.  Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.

Authors:  Christoffer Clemmensen; Brian Finan; Katrin Fischer; Robby Zachariah Tom; Beata Legutko; Laura Sehrer; Daniela Heine; Niklas Grassl; Carola W Meyer; Bart Henderson; Susanna M Hofmann; Matthias H Tschöp; Lex H T Van der Ploeg; Timo D Müller
Journal:  EMBO Mol Med       Date:  2015-03       Impact factor: 12.137

9.  Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques.

Authors:  Paul Kievit; Heather Halem; Daniel L Marks; Jesse Z Dong; Maria M Glavas; Puspha Sinnayah; Lindsay Pranger; Michael A Cowley; Kevin L Grove; Michael D Culler
Journal:  Diabetes       Date:  2012-10-09       Impact factor: 9.461

10.  Reprogramming the body weight set point by a reciprocal interaction of hypothalamic leptin sensitivity and Pomc gene expression reverts extreme obesity.

Authors:  Kavaljit H Chhabra; Jessica M Adams; Graham L Jones; Miho Yamashita; Martin Schlapschy; Arne Skerra; Marcelo Rubinstein; Malcolm J Low
Journal:  Mol Metab       Date:  2016-08-05       Impact factor: 7.422
  10 in total
  6 in total

Review 1.  Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.

Authors:  Gitanjali Srivastava; Caroline Apovian
Journal:  Curr Obes Rep       Date:  2018-06

Review 2.  Genetic Determinants of Childhood Obesity.

Authors:  Sheridan H Littleton; Robert I Berkowitz; Struan F A Grant
Journal:  Mol Diagn Ther       Date:  2020-10-01       Impact factor: 4.074

Review 3.  The Role of Obesity and Diabetes in Dementia.

Authors:  Ashley Selman; Scott Burns; Arubala P Reddy; John Culberson; P Hemachandra Reddy
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

4.  Brain atlas for glycoprotein hormone receptors at single-transcript level.

Authors:  Vitaly Ryu; Anisa Gumerova; Funda Korkmaz; Seong Su Kang; Pavel Katsel; Sari Miyashita; Hasni Kannangara; Liam Cullen; Pokman Chan; TanChun Kuo; Ashley Padilla; Farhath Sultana; Soleil A Wizman; Natan Kramskiy; Samir Zaidi; Se-Min Kim; Maria I New; Clifford J Rosen; Ki A Goosens; Tal Frolinger; Vahram Haroutunian; Keqiang Ye; Daria Lizneva; Terry F Davies; Tony Yuen; Mone Zaidi
Journal:  Elife       Date:  2022-09-02       Impact factor: 8.713

5.  Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.

Authors:  Kristin L Ayers; Benjamin S Glicksberg; Alastair S Garfield; Simonne Longerich; Joseph A White; Pengwei Yang; Lei Du; Thomas W Chittenden; Jeffery R Gulcher; Sophie Roy; Fred Fiedorek; Keith Gottesdiener; Sarah Cohen; Kari E North; Eric E Schadt; Shuyu D Li; Rong Chen; Lex H T Van der Ploeg
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

Review 6.  Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications.

Authors:  Min Gong; Song Wen; Thiquynhnga Nguyen; Chaoxun Wang; Jianlan Jin; Ligang Zhou
Journal:  Diabetes Metab Syndr Obes       Date:  2020-03-30       Impact factor: 3.168
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.